Rain Oncology reports Q3 EPS (19c), consensus (27c)

As of September 30, Rain had $77.3M in cash, cash equivalents and short-term investments. “Rain continues to evaluate a number of strategic opportunities to add value for its stockholders,” said Avanish Vellanki, co-founder and chief executive officer of Rain. “We anticipate being able to provide a public update on our efforts before the end of the year.”